A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

NCT03467373 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

111

Enrollment

INDUSTRY

Sponsor class

Conditions

B-Cell Lymphoma
Non-Hodgkin Lymphoma

Interventions

DRUG: Glofitamab
DRUG: Obinutuzumab (G)
DRUG: Rituximab (R)
DRUG: Tocilizumab
DRUG: Cyclophosphamide
DRUG: Doxorubicin
DRUG: Vincristine
DRUG: Prednisone
DRUG: Polatuzumab vedotin

Sponsor

Hoffmann-La Roche